Ketamine-assisted psychotherapy combines medically supervised ketamine treatment with psychological support. It may be considered for selected people after specialist assessment, particularly when depression has not responded adequately to other treatment. At Pathways, discussion begins with your needs, previous care and suitable options. Availability, local requirements and the appropriate treatment setting must be confirmed before any programme is agreed.
Feeling better is closer than you think
Understanding ketamine-assisted therapy
What is ketamine-assisted psychotherapy?
Ketamine is a dissociative anaesthetic that can alter perception and the sense of connection to the body. Although sometimes discussed alongside classic psychedelics, it is a different type of medicine. Its psychiatric use requires careful medical assessment and supervision.
Ketamine-assisted psychotherapy combines the medication experience with therapeutic preparation, support and subsequent reflection. It is distinct from ketamine treatment delivered without a structured psychotherapy component. The suitability of either approach depends on your clinical needs; a dissociative experience is not itself proof of therapeutic benefit.
How could it fit into my programme?
Specialist assessment considers your symptoms, previous treatments, medical history, other medicines, substance use and preferences. Treatment-resistant depression (TRD) is an important area of clinical use and research. Any discussion must weigh potential benefit against risks and alternative options.
Ketamine is also used in some specialist pain services. Research explores psychiatric applications including anxiety, post-traumatic stress disorder, substance use disorders and eating disorders, but the evidence and regulatory status differ. These uses should not be treated as equally established or assumed to be available within a Pathways programme.
Understanding the different formulations
Racemic ketamine contains two molecular forms; esketamine is one of them. Spravato is a specific esketamine nasal-spray product. Intravenous ketamine and compounded nasal preparations are different products with different evidence, absorption and prescribing requirements.
A proprietary or compounded spray is not interchangeable with an authorised product. The formulation and route must be selected by an appropriately qualified prescriber, with consideration of clinical needs and local rules. Nasal administration is not necessarily faster than intravenous administration, and superiority for people with co-occurring diagnoses cannot be assumed.
What happens during supervised treatment?
Treatment requires an appropriate clinical setting, a prescribing clinician and trained staff able to monitor and respond to adverse effects. Experiences may include dissociation, altered perception, dizziness, nausea, sedation or changes in blood pressure. Alertness can be impaired; remaining fully conscious cannot be guaranteed.
Therapeutic support may help you prepare for the experience and reflect on emotions or memories afterwards. Monitoring extends beyond the immediate medication effects. For example, US Spravato requirements include at least two hours of observation. A 45–60 minute experience should not be confused with the full clinical appointment.
Is the approach evidence-based?
Evidence supports a rapid antidepressant effect from ketamine or esketamine for some people with TRD, but response is not universal. In the United States, Spravato has authorised adult depression indications, whereas racemic ketamine is not FDA-approved for psychiatric disorders. These distinctions do not establish approval or availability in Pakistan.
Evidence for the medication should also be distinguished from evidence for a particular ketamine-assisted psychotherapy protocol. Research on that combination and on other psychiatric conditions is developing. Early improvement does not guarantee lasting remission; follow-up and an ongoing treatment plan remain important.
How might ketamine affect the brain?
Ketamine acts on glutamate-related signalling, including NMDA receptors. Researchers are studying how its downstream effects may influence synaptic function and neuroplasticity: the brain’s capacity to change connections. These mechanisms are complex and do not mean the brain is literally “reset”.
Some people experience improvement within hours or days, while others do not benefit or need continuing care. No single-session response percentage applies to every person or formulation. Treatment frequency, duration and monitoring must be clinically determined rather than promised as a daily or weekly schedule. Misuse, dependence and other adverse effects also require consideration.
